AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
This article was originally published in The Pink Sheet Daily
Executive Summary
Exclusive license adds to AMAG's cash reserves and further validates the anemia drug's safety profile
You may also be interested in...
Investors Balk At AMAG-Allos Proposed Marriage
An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.
Investors Balk At AMAG-Allos Proposed Marriage
An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.